Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Y Wen

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Histopathology|April 24, 2019
Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potentialRaza S Hoda, Edi Brogi, Fresia Pareja, et al.
Archives of Pathology & Laboratory Medicine|October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0Raza S Hoda, Edi Brogi, Jin Xu, et al.
Histopathology|August 26, 2020
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelineRaza S Hoda, Anita S Bowman, Ahmet Zehir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2016
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasSaya H Ebbesen, Maurizio Scaltriti, Carl U Bialucha, et al.
Breast Cancer Research and Treatment|July 27, 2016
Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelinesXiao-Long Qian, Hannah Y Wen, Yi-Ling Yang, et al.
Breast Cancer Research and Treatment|May 31, 2019
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapyMelissa Krystel-Whittemore, Jin Xu, Edi Brogi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 3, 2021
Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genesChristopher J Schwartz, Fresia Pareja, Edaise M da Silva, et al.
Pathology Oncology Research : POR|September 13, 2024
Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practiceChiu-Hsiang Connie Liao, Nilay Bakoglu, Emine Cesmecioglu, et al.
Cancer|August 16, 2016
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-upHannah Y Wen, Melissa Krystel-Whittemore, Sujata Patil, et al.
The American Journal of Surgical Pathology|February 12, 2025
Breast Carcinomas Resembling Acinic Cell Carcinoma: Comprehensive Analysis of 14 Cases and Review of the LiteratureFengxia Qin, Jiazhen Li, Yi Zheng, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Histopathology|April 24, 2019
Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potentialRaza S Hoda, Edi Brogi, Fresia Pareja, et al.
Archives of Pathology & Laboratory Medicine|October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0Raza S Hoda, Edi Brogi, Jin Xu, et al.
Histopathology|August 26, 2020
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelineRaza S Hoda, Anita S Bowman, Ahmet Zehir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2016
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasSaya H Ebbesen, Maurizio Scaltriti, Carl U Bialucha, et al.
Breast Cancer Research and Treatment|July 27, 2016
Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelinesXiao-Long Qian, Hannah Y Wen, Yi-Ling Yang, et al.
Breast Cancer Research and Treatment|May 31, 2019
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapyMelissa Krystel-Whittemore, Jin Xu, Edi Brogi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 3, 2021
Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genesChristopher J Schwartz, Fresia Pareja, Edaise M da Silva, et al.
Pathology Oncology Research : POR|September 13, 2024
Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practiceChiu-Hsiang Connie Liao, Nilay Bakoglu, Emine Cesmecioglu, et al.
Cancer|August 16, 2016
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-upHannah Y Wen, Melissa Krystel-Whittemore, Sujata Patil, et al.
The American Journal of Surgical Pathology|February 12, 2025
Breast Carcinomas Resembling Acinic Cell Carcinoma: Comprehensive Analysis of 14 Cases and Review of the LiteratureFengxia Qin, Jiazhen Li, Yi Zheng, et al.
Pageof 11